|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | |||||||||||
| Cash and cash equivalents | |||||||||||
| Restricted cash | |||||||||||
| Accounts receivable, net | |||||||||||
| Inventory | |||||||||||
| Due from Chromocell Corporation | |||||||||||
| Deferred offering costs | |||||||||||
| Prepaid expenses and other current assets | |||||||||||
| Total current assets | |||||||||||
| Property and equipment, net | |||||||||||
| Operating lease right-of-use assets, net | |||||||||||
| Intangible assets, net | |||||||||||
| Goodwill | |||||||||||
| Total assets | |||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Accounts payable and accrued expenses | |||||||||||
| Accounts payable | |||||||||||
| Accrued expenses | |||||||||||
| Investor Note, net of debt discount | |||||||||||
| Contingent consideration | |||||||||||
| Operating lease liabilities, current portion | |||||||||||
| Loan payable, net of debt discount | |||||||||||
| Loan payable - related party, net of debt discount | |||||||||||
| Due to Chromocell Corporation | |||||||||||
| Deferred revenue, current portion | |||||||||||
| Other liabilities | |||||||||||
| Nonrelated Party | |||||||||||
| Related Party | |||||||||||
| Total other liabilities | |||||||||||
| Total current liabilities | |||||||||||
| Deferred income tax liability | |||||||||||
| Operating lease liabilities, net of current portion | |||||||||||
| Deferred revenue, net of current portion | |||||||||||
| Convertible notes payable - related party | |||||||||||
| Related Party | |||||||||||
| Total convertible notes payable - related party | |||||||||||
| Venture loan and security agreement, net | |||||||||||
| Other long-term liabilities | |||||||||||
| Nonrelated Party | |||||||||||
| Related Party | |||||||||||
| Total other long-term liabilities | |||||||||||
| Liabilities | |||||||||||
| Related Party | |||||||||||
| Total liabilities | |||||||||||
| STOCKHOLDERS’ EQUITY | |||||||||||
| Preferred stock, value | |||||||||||
| Common stock, value | |||||||||||
| Additional paid in capital | |||||||||||
| Accumulated other comprehensive income | |||||||||||
| Accumulated deficit | |||||||||||
| Stockholders' (deficit) equity | |||||||||||
| Preferred stock series A | |||||||||||
| Preferred stock series C | |||||||||||
| Total stockholders' (deficit) equity | |||||||||||
| Total liabilities and stockholders' equity |
Loading...
